Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

721. Schizophrenia, Consensus statement

Schizophrenia, Consensus statement Schizophrenia, Consensus statement Schizophrenia, Consensus statement The Danish Medical Research Council and the Danish Hospital Institute Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation The Danish Medical Research Council and the Danish Hospital Institute. Schizophrenia, Consensus statement. Danish (...) Institute for Health Services Research (DSI). 1993 Authors' objectives To provide an overview of activities and problems concerning schizophrenia, and thereby forward the diffusion of expert knowledge to the public. Authors' conclusions There is a need for further coordination of the psychiatric, the psychologic, and the social efforts. There is also a need for an increase in research, development and education. Other output or dissemination activity: Impact not evaluated. Project page URL Indexing

1993 Health Technology Assessment (HTA) Database.

722. PARTIAL TRISOMY CHROMOSOME 5 COSEGREGATING WITH SCHIZOPHRENIA (PubMed)

PARTIAL TRISOMY CHROMOSOME 5 COSEGREGATING WITH SCHIZOPHRENIA Schizophrenia was associated with a distinct autosomal abnormality in two related mildly dysmorphic individuals. The finding of cosegregation of schizophrenia and a partial trisomy of chromosome 5 in the family suggests a potential location of a gene or genes linked to schizophrenia.

Full Text available with Trip Pro

1988 Lancet

723. The therapeutic efficacy of hemodialysis in schizophrenia. (PubMed)

The therapeutic efficacy of hemodialysis in schizophrenia. Prompted by previous reports of substantial clinical improvement in most schizophrenic patients given hemodialysis for their psychiatric condition, we studied the efficacy of hemodialysis in 15 schizophrenic outpatients, under double-blind, controlled conditions. The patients were randomly assigned to either a real-sham or sham-real sequence of dialysis treatment. Results of repeated measurement and other analyses of data on symptoms (...) and behavior that were collected before study treatment, at crossover, and at the end of treatment revealed no difference between the effects of real and sham dialysis. These results provide important experimental evidence of the lack of therapeutic efficacy of hemodialysis in schizophrenia.

1983 NEJM

724. Family management in the prevention of exacerbations of schizophrenia: a controlled study. (PubMed)

Family management in the prevention of exacerbations of schizophrenia: a controlled study. Environmental stress has been implicated as an important factor in the relapse of schizophrenic patients receiving optimal drug therapy. In a randomized controlled study, we compared at-home family therapy with clinic-based individual supportive care in the community management of schizophrenia in 36 patients taking neuroleptic maintenance medications. The family-treatment approach sought to enhance

1982 NEJM

725. ECT for schizophrenia. (PubMed)

ECT for schizophrenia. Electroconvulsive therapy (ECT) in the treatment of schizophrenia was evaluated in a double-blind trial; the clinical change after ECT was compared with that after a treatment procedure identical to it but for two exceptions--no electricity was used and no convulsion was induced. All patients had paranoid schizophrenia according to Present State Examination criteria and all received standard doses of neuroleptics for at least 2 weeks before random assignment to the two

1980 Lancet

726. Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. (PubMed)

Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. In a double-blind trial in which 45 patients with acute schizophrenia took part the alpha-isomer of flupenthixol (which blocks the dopamine receptor) was found to be significantly more effective than both beta-flupenthixol (which does not) and placebo. The drug effect was confined to the "positive" symptoms--delusions, hallucinations, and though disorder--and appeared only in the 3rd and 4th weeks of the trial (...) . It was as great in patients with evidence of deterioration (Feighner-positive patients) as in patients without deterioration and was less in patients who had affective disturbance in addition to schizophrenia symptoms. The findings are consistent with the hypothesis that dopamine-receptor blockade is the only requirement for antipsychotic activity and suggest that the antipsychotic effect occurs in patients with typically schizophrenic illnesses but may be limited to positive symptoms.

1978 Lancet

727. Propranolol as an adjunct to the treatment of schizophrenia. (PubMed)

Propranolol as an adjunct to the treatment of schizophrenia. Propranolol contributed usefully to the practical management of patients with chronic schizophrenia whose florid symptoms had not remitted with major tranquillisers. 14 patients who had received an average equivalent of 954 mg per day of chlorpromazine for 10 years were given, in addition, either propranolol or a placebo for 12 weeks. Both groups had improved by the twelfth week, but the propranolol group had improved significantly

1977 Lancet

728. Editorial: Dietary factors and schizophrenia. (PubMed)

Editorial: Dietary factors and schizophrenia. 937890 1976 08 23 2004 11 17 0003-4819 84 6 1976 Jun Annals of internal medicine Ann. Intern. Med. Editorial: Dietary factors and schizophrenia. 745 Kety S S SS eng Clinical Trial Journal Article Randomized Controlled Trial United States Ann Intern Med 0372351 0003-4819 AIM IM Diet adverse effects Humans Schizophrenia diet therapy etiology 1976 6 1 1976 6 1 0 1 1976 6 1 0 0 ppublish 937890

1976 Annals of Internal Medicine